Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Undersøgelse af BDTX-1535 hos deltagere med glioblastom eller ikke-småcellet lungekræft

13. november 2026 opdateret af: Black Diamond Therapeutics, Inc.

Et fase 1-studie til vurdering af BDTX-1535, en oral EGFR-hæmmer, hos deltagere med glioblastom eller ikke-småcellet lungekræft

BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of silevertinib (BDTX-1535). The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma (GBM) expressing EGFR alterations (Phase 1 only). All patients will self-administer silevertinib (BDTX-1535) monotherapy by mouth in 21-day cycles.

Phase 1 enrollment is now complete. Phase 2 is currently ongoing.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

220

Fase

  • Fase 2
  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • British Columbia
      • Vancouver, British Columbia, Canada, V5Z 4E6
    • Ontario
      • Toronto, Ontario, Canada, M5G 1X5
        • Rekruttering
        • The Princess Margaret Cancer Centre
        • Kontakt:
    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35294
        • Rekruttering
        • University of Alabama
        • Kontakt:
    • Arizona
      • Gilbert, Arizona, Forenede Stater, 85234
    • California
      • Irvine, California, Forenede Stater, 92618
        • Rekruttering
        • City of Hope Orange County Lennar Foundation Cancer Center
        • Kontakt:
          • Telefonnummer: 626-218-1133
        • Kontakt:
          • Diana Patterson
          • Telefonnummer: 949-671-4763
      • Los Angeles, California, Forenede Stater, 90048
        • Rekruttering
        • Cedars Sinai Medical Center
        • Kontakt:
    • District of Columbia
      • Washington D.C., District of Columbia, Forenede Stater, 20016
    • Florida
      • Jacksonville, Florida, Forenede Stater, 32224
        • Rekruttering
        • Mayo Clinic- Jacksonville
        • Kontakt:
          • Yanyan Lou
          • Telefonnummer: 855-776-0015
      • Miami, Florida, Forenede Stater, 33176
        • Rekruttering
        • Miami Cancer Institute - Baptist Health South Florida
        • Kontakt:
    • Hawaii
      • Honolulu, Hawaii, Forenede Stater, 96813
        • Rekruttering
        • UHP- University of Hawaii Cancer Center
        • Kontakt:
          • Evan Wu, MD
          • Telefonnummer: 808-586-3010
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60611
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02115
    • Minnesota
      • Rochester, Minnesota, Forenede Stater, 55905
        • Rekruttering
        • Mayo Clinic- Rochester
        • Kontakt:
          • Anastasios Dimou, MD
          • Telefonnummer: 855-776-0015
    • New York
      • The Bronx, New York, Forenede Stater, 10461
        • Rekruttering
        • Montefiore Medical Center
        • Kontakt:
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forenede Stater, 15232
        • Rekruttering
        • University of Pittsburgh Medical Center - Hillman Cancer Center
        • Kontakt:
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37203
        • Rekruttering
        • Tennessee Oncology
        • Kontakt:
    • Virginia
      • Fairfax, Virginia, Forenede Stater, 22031
      • Fairfax, Virginia, Forenede Stater, 22031
    • Washington
      • Seattle, Washington, Forenede Stater, 98109
        • Rekruttering
        • Fred Hutchinson Cancer Center/University of Washington
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Phase 2 Eligibility:

Key Inclusion Criteria Required for locally advanced or metastatic NSCLC:

  • Measurable disease by RECIST 1.1 criteria.

  • Adequate bone marrow or organ function.

  • Life expectancy of ≥ 3 months.

  • Sufficient performance status.

  • Confirmed NSCLC, without small cell lung cancer transformation with or without brain metastases.

  • Disease progression following or intolerance of standard of care (excluding patients in the treatment-naïve non-classical driver cohort):

    • Cohort 1 (Non-Classical driver cohort): Advanced/metastatic NSCLC with a non-classical driver EGFR mutation (eg, G719X) following up to 2 lines of therapy with only 1 prior EGFR TKI regimen (third-generation preferred; other approved EGFR TKI acceptable).
    • Cohort 2 (Acquired resistance C797S cohort): Advanced/metastatic NSCLC with the acquired resistance C797S EGFR mutation following up to 2 lines of therapy, including only one EGFR TKI, which must be a third generation EGFR TKI (eg, osimertinib).
    • Cohort 3 and 4 (First-line non-classical driver cohort): Treatment-naïve advanced/metastatic NSCLC with a non-classical driver EGFR mutations (1 cycle of chemotherapy or immune checkpoint inhibitor are permitted). Patients with co-occurring L858R mutations and a non-classical mutation are eligible for inclusion.
  • Identification of one (or more) of the following EGFR mutations by Next Generation Sequencing (NGS) as determined by a local assay performed in a validated laboratory in the absence of other known resistance mutations (eg, T790M, MET):

    • Non-classical driver EGFR mutations (eg, L861R, S768I, G719X).
    • EGFR acquired resistance mutation (eg, C797S) to a 3rd generation EGFR TKI.
    • For Phase 2, dose expansion, patients in Cohort 1 who received 3rd generation EGFR TKI (eg, osimertinib), the NGS report within 6 months prior to the start of Screening is acceptable. For patients in Cohort 2, the NGS report must be from the last disease progression on the immediate prior therapy. For patients in Cohort 3 and 4, the NGS report must be at the time of diagnosis.

Key Exclusion Criteria:

  • Known resistant mutations in tumor tissue or by liquid biopsy (eg, T790M, MET).
  • Received more than 1 EGFR TKI therapy (ie, erlotinib or gefitinib) for the treatment of metastatic or recurrent EGFR NSCLC.
  • Any history of interstitial lung disease related to EGFR TKI use.
  • Symptomatic or radiographic leptomeningeal disease.
  • Symptomatic brain metastases or spinal cord compression requiring urgent clinical intervention.
  • Unresolved toxicity from prior therapy.
  • Significant cardiovascular disease.
  • Major surgery within 4 weeks of study entry or planned during study.
  • Ongoing or recent anticancer therapy or radiation therapy.
  • Evidence of malignancy (other than study-specific malignancies) requiring active therapy within the next 2 years.
  • Active hepatitis B or C infection and/or known human immunodeficiency virus (HIV) carrier.
  • Poorly controlled gastrointestinal disorders.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Phase 1 Dose Escalation - Monotherapy (Recruitment Closed)
  • Advanced/metastatic NSCLC with acquired resistance EGFR mutation (eg, C797S), following a 3rd generation EGFR inhibitor in the 1st line setting (in the absence of concurrent T790M).
  • Advanced/metastatic NSCLC with non-classical EGFR mutation (eg, G719X) following standard-of-care therapy with an EGFR inhibitor
  • Recurrent GBM with confirmed EGFR alterations (including amplification, mutation, and/or variant)

Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.

Andre navne:
  • BDTX-1535
Eksperimentel: Phase 2 Cohort 1: NSCLC EGFR Non-Classical Driver Mutations (Recruitment Closed)

Advanced/metastatic NSCLC with a non-classical driver EGFR mutation following up to 2 lines of therapy with only 1 prior EGFR targeted regimen (third-generation preferred; other approved EGFR inhibitors acceptable)

Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.

Andre navne:
  • BDTX-1535
Eksperimentel: Phase 2 Cohort 2: NSCLC EGFR Acquired Resistance (C797S) Mutation (Recruitment Closed)

Advanced/metastatic NSCLC with the acquired resistance C797S EGFR mutation following up to 2 lines of therapy, including only 1 EGFR targeted regimen, which must be a third generation EGFR TKI (eg, osimertinib)

Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.

Andre navne:
  • BDTX-1535
Eksperimentel: Phase 2 Cohort 3: Treatment Naive NSCLC EGFR Non-Classical Driver Mutations (Recruitment Closed)

Treatment-naïve (first-line) advanced/metastatic NSCLC with a non-classical driver EGFR mutation (1 cycle of chemotherapy or immune checkpoint inhibitor are permitted). Patients with co-occurring L858R mutations and a non-classical mutation are eligible for inclusion. Silevertinib dose for Cohort 3 is 200 mg QD.

Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.

Andre navne:
  • BDTX-1535
Eksperimentel: Phase 2 Cohort 4: Treatment Naive NSCLC EGFR Non-Classical Driver Mutations at 150 mg QD Dose

Treatment-naïve (first-line) advanced/metastatic NSCLC with a non-classical driver EGFR mutation (1 cycle of chemotherapy or immune checkpoint inhibitor are permitted). Patients with co-occurring L858R mutations and a non-classical mutation are eligible for inclusion. Silevertinib dose for Cohort 4 is 150 mg QD.

Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.

Andre navne:
  • BDTX-1535

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Phase 1 Dose Escalation: To determine the maximum tolerated dose (MTD), if one exists, and the preliminary recommended Phase 2 dose(s) (RP2D[s]) of silevertinib (BDTX-1535)
Tidsramme: The first treatment 21-day cycle (Cycle 1)

Dose-limiting toxicities (DLTs) in Cycle 1

The first treatment 21-day cycle (Cycle 1)
Phase 2 (Cohorts 1, 2, and 3): To assess antitumor efficacy of silevertinib (BDTX-1535)
Tidsramme: Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)

Objective response rate (ORR) as assessed by Investigator using RECIST version 1.1

Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)
Phase 2 Cohort 4 Only: To assess the safety and tolerability of silevertinib at the 150 mg QD dose
Tidsramme: Through study completion, approximately 1 year

Treatment-emergent adverse events

Through study completion, approximately 1 year

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Fase 2: At vurdere progressionsfri overlevelse med RECIST version 1.1
Tidsramme: Dag 1 hver anden cyklus starter ved cyklus 3 Dag 1 til studieafslutning, cirka 1 år (hver cyklus er 21 dage)
Dag 1 hver anden cyklus starter ved cyklus 3 Dag 1 til studieafslutning, cirka 1 år (hver cyklus er 21 dage)
Fase 1: At vurdere den foreløbige antitumoraktivitet af Silevertinib (BDTX-1535) ved objektiv respons som vurderet af RECIST version 1.1 (for patienter med NSCLC) eller responsvurdering i neuro-onkologi (RANO) (for patienter med GBM)
Tidsramme: Dag 1 hver 2. cyklus, der starter på cyklus 3 dag 1 for at studere færdiggørelse, cirka 1 år (hver cyklus er 21 dage)
Dag 1 hver 2. cyklus, der starter på cyklus 3 dag 1 for at studere færdiggørelse, cirka 1 år (hver cyklus er 21 dage)
Phase 2 Cohort 4 Only: To assess antitumor efficacy of silevertinib (BDTX-1535)
Tidsramme: Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)

Objective response rate (ORR) as assessed by Investigator using RECIST version 1.1

Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Black Diamond Therapeutics, Black Diamond Therapeutics

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

31. marts 2022

Primær færdiggørelse (Anslået)

1. marts 2028

Studieafslutning (Anslået)

1. juni 2028

Datoer for studieregistrering

Først indsendt

15. februar 2022

Først indsendt, der opfyldte QC-kriterier

24. februar 2022

Først opslået (Faktiske)

25. februar 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

18. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

13. november 2026

Sidst verificeret

1. juli 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .